.jpg)
.png)
Spring 2022
What a year 2021 was! Despite continued disruption of the COVID-19 pandemic, members of the Pacific Lipid Association (PLA) chapter were busy providing clinical care, advancing research, and publishing in all areas related to lipid management. This issue of LipidSpin is a collaboration between MWLA... more
Q: Why do you support DE and I for NLA? In general terms, I am a very strong supporter of DEI as a core foundational principle for all organizations. Specifically, for the NLA, integration of DEI is critical to ensure that the vision, mission, and goals for the organization are reflective of the... more
Inclisiran (Leqvio; Novartis) is now the first small interfering RNA (siRNA) therapy to be approved by the FDA to reduce low-density lipoprotein cholesterol (LDL-C). Inclisiran was previously approved in the EU on 9 December 2020 for use in adults with primary hypercholesterolemia (heterozygous... more
This issue is co-sponsored by the Midwest and Pacific Lipid Associations
Hello everyone, Happy New Year! Being on the downslope of a recent peak in infection rates brings hope to those of us on the front lines of battling the pandemic. I have hope that we soon will be able to attain a sense of “normal”. As we enter the new year, there are so many exciting... more
The theme of the current issue of LipidSpin is, “New Approaches for Managing Atherogenic Particles.” We are in the midst of a very exciting and interesting time to be treating atherogenic particles. Statins have revolutionized the care of patients with atherosclerotic cardiovascular... more